医药出口回归常态，传统贸易加速转型 - 2023年中国医药外贸分析与2024年展望
2023年中国医药外贸总体情况
2023年，中国医药健康产品进出口总额为1953.7亿美元，同比下降11.1%。其中出口额1020.6亿美元，同比下降20.7%；进口额933.1亿美元，同比增长2.4%。
Major Figures of China's Pharmaceutical Foreign Trade in 2023
The total import and export volume of China's pharmaceutical health products in 2023 was $195.37 billion, a decrease of 11.1% year-on-year. Exports were $102.06 billion (down 20.7%), while imports reached $93.31 billion (up 2.4%).
出口产品结构分析
按金额占比计算：
- 西药类 50%
- 医疗器械类 44.6%
- 中药类 5.4%
Export Product Structure Analysis
By value proportion:
- Western medicines 50%
- Medical devices 44.6%
- Traditional Chinese medicines 5.4%
主要出口市场表现
2023年主要贸易伙伴：
- 欧盟及英国：705亿美元(-8%)
- 美国：327.9亿美元(-12.3%)
- 东盟：161.4亿美元(-17.9%)
Performance in Major Export Markets
Main trading partners in 2023:
- EU & UK: $70.5 billion (-8%)
- USA: $32.79 billion (-12.3%)
- ASEAN: $16.14 billion (-17.9%)
行业发展趋势
1. 医药外贸回归常态
2023年第四季度出口降幅缩至8.5%，大部分医药产品出口恢复常态。
2. 传统贸易加速转型
企业从单纯贸易转向海外设厂、参股等深度合作模式。
3. 创新药出海进入收获期
2023年国产新药海外授权金额超400亿美元，多个创新药在欧美获批。
Industry Development Trends
1. Pharmaceutical Foreign Trade Returns to Normal
The export decline narrowed to 8.5% in Q4 2023, with most pharmaceutical exports returning to normal levels.
2. Accelerated Transformation of Traditional Trade
Companies are shifting from simple trade to deeper cooperation models like overseas factories and equity participation.
3. Harvest Period for Innovative Drug Globalization
In 2023, overseas licensing of domestic innovative drugs exceeded $40 billion, with several new drugs approved in Europe and the US.
2024年展望
1. 传统医药产品出口有望触底回升
2. 创新药械进口将继续加速
3. 新兴市场将成为重点开拓方向
2024 Outlook
1. Traditional pharmaceutical exports expected to bottom out and recover
2. Continued acceleration in innovative drug and device imports
3. Emerging markets will become key development directions
